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ABSTRACT
Background: Doxorubicin is an antineoplastic agent that causes skin necrosis
when extravasated. Various agents have been tried to reduce tissue damage owing to
extravasation. Erythropoietin (EPO) is an obligatory growth factor for red blood cells
and has beneficial effects on wound healing.
Objective: The aim of this study was to test the hypothesis that local EPO injection
an prevent and improve healing of necrosis at the doxorubicin injection site in rats.
Methods: We used 31 female Sprague-Dawley rats. The dorsal area of each rat
was shaved, and 2 mg of doxorubicin in 0.5 mL saline was injected intradermally. The
rats were then divided into 3 groups: control; control with intradermal injection of
saline; and treatment, which received an intradermal injection of EPO. EPO in saline
was injected into 4 quadrants of the same site where doxorubicin was injected 1 hour
before. The rats were monitored and the area of each ulcer was measured. Skin
biopsies were excised at the end of 4 weeks using anesthetic pentobarbital. Inflam-
mation, edema, epithelization, neovascularization, necrosis, fibroblast proliferation,
and collagen synthesis were evaluated and compared between groups.
Results: The average areas of the lesions were significantly smaller in the
PO-injected rats (P  0.03). The histopathologic evaluation revealed that the
cores for epithelization, neovascularization, fibroblast proliferation, and collagen
ynthesis were higher (P  0.001, P  0.001, P  0.002, and P  0.04,
espectively) and the score for necrosis was lower (P  0.001) in the EPO-injected
roup than in both the saline-injected and control groups.
Conclusions: In this study using female Sprague-Dawley rats, EPO treatment
improved the healing of skin necrosis caused by doxorubicin injection. This finding may lead
to a new therapeutic approach for the management of skin necrosis caused by doxorubicin
extravasation. (Curr Ther Res Clin Exp. 2011;72:141-149) © 2011 Elsevier HS Journals, Inc.
Accepted for publication June 30, 2011. doi:10.1016/j.curtheres.2011.07.001
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INTRODUCTION
Doxorubicin is an anthracycline antibiotic widely used as an antineoplastic agent.1 It
is used in standard chemotherapeutic regimens for many hematopoietic malignancies
and solid tumors. Leakage of intravenous infusions from the intravascular region into
the interstitial space is called extravasation, and local skin necrosis after extravasation
of doxorubicin is a common problem.2 In large series, the incidence of necrosis owing
o extravasation has been reported to occur in 6% of cancer patients treated with
hemotherapy.3 The lesion starts as a local toxicity with pain and erythema and may
progress to tissue necrosis.2 Doxorubicin causes cellular death with direct toxic effects
o living cells and results in the release of a doxorubicin-DNA complex into the
ntercellular space.2 This process prevents the release of the cytokines and growth
factors that participate in wound healing.4,5 Thus, this type of ulcer heals much more
slowly than other types.6
Wound healing is a complex process that is initiated by tissue injury and involves
nflammation, proliferation, migration, angiogenesis, matrix synthesis, collagen de-
osition, re-epithelization, neovascularization, and formation of granulation tissue.7,8
The process uses an interplay of cells, mediators, growth factors, and cytokines.9 It
egins with clotting and the recruitment of inflammatory cells and proceeds to a
ighly proliferative state. During the proliferative phase angiogenesis occurs, and the
ormation of new blood vessels provides oxygen and nutrient delivery.9 Healing is also
concomitant with the release of angiogenic growth factors such as vascular endothelial
growth factor (VEGF), fibroblast growth factor, and platelet-derived growth factor.10
Erythropoietin (EPO) is a 34-kDa glycoprotein and an obligatory growth factor for
ed blood cell proliferation, maturation, and differentiation.7,11 The biological effects
of EPO are mediated by its specific cell-surface receptor, erythropoietin receptor
(EPOR), which is a type of cytokine receptor that is present on erythroid progenitor
cells as well as several nonhematopoietic cell types.8,12,13 Many studies suggest that
the functions of EPO and EPOR are not strictly limited to red blood cells.14 EPOR
expression has been shown in other tissues, such as the kidneys, muscle cells, and
intestine, and is associated with cellular proliferation. Vascular endothelial cells also
express EPOR, and studies have shown that EPO stimulates angiogenesis.8 EPO can
timulate the first phase of angiogenesis, which includes increased cellular motility,
reakdown of the cell matrix, and cellular proliferation.12 In addition, EPO is known
o induce a pro-angiogenic phenotype in cultured endothelial cells and to stimulate
eovascularization in the chick chorioallantoic membrane.15 Carlini et al16 demon-
strated that EPO may stimulate vessel growth of rat aortic rings embedded in culture.
In a review by Burger et al,17 the angiogenesis-promoting effect of EPO, which is
ndependent of its erythropoietic effect, was emphasized, although all the molecular
echanisms could not be explained. EPO also improves wound repair by promoting
evascularization and microvascular remodeling.18 Moreover, the interaction between
PO and VEGF may be important in the complex phenomenon of wound healing.9
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N.S¸.Y. Bilge et al.Many treatment options, such as local and systemic pharmacological agents
nd surgery, have been tried for skin necrosis caused by doxorubicin.2 In the
resent study, we investigated the potential beneficial effects of local EPO
njection on preventing and healing tissue damage in a rat model of doxorubicin
xtravasation.
MATERIALS AND METHODS
Study Design
The experiment was performed in 31 female Sprague-Dawley rats, weighing
00 to 250 g, supplied by Eskisehir Osmangazi University Medical Faculty,
edical and Surgical Research Center (Eskisehir, Turkey). Laboratory food and
ater were provided ad libitum. Following ether anesthesia, 2 mg of doxorubicin
n 0.5 mL saline was injected intradermally into the dorsal skin of all animals.
he animals were then divided into 3 groups: control, control with saline, and
reatment. In the control group (n  11), no additional injection was given. In
he control group with saline (n  10), 0.1 mL saline was administered intrad-
rmally into 4 quadrants of the doxorubicin injection site 1 hour after the
oxorubicin injection. In the treatment group (n  10), EPO (400 IU/kg epoetin
eta [recombinant human erythropoietin]) in saline was administered intrader-
ally into 4 quadrants of the doxorubicin injection site 1 hour after the doxo-
ubicin injection. The total volume of EPO and saline was equal to the volume
f saline injected into the control with saline group.
The development and progression of skin necrosis was monitored at a regular
nterval. The area of necrosis was measured every 7 days by an investigator who was
lind to group allocation. Ulcers developed in all doxorubicin-injected animals. At
he end of 1 month, we calculated the area of each ulcer by measuring the 2 greatest
erpendicular diameters of the lesion and using those measurements in the formula
eported in the study by Vargel et al19: (a  b)/2.
At conclusion of the experiment, 1 month after doxorubicin injection, the entire
ulcerated skin and underlying tissues from all animals were excised under pentobar-
bital anesthesia (80 mg/kg injected intraperitoneally) and the remaining dorsal areas
were sutured. The tissues underwent routine tissue processing procedures for paraffin
embedding following fixation in 10% formalin and were stained with hematoxylin
and eosin.
The study design was approved by the local ethics committee and is in accordance
with the Declaration of Helsinki.
Histopathologic Evaluation
The pathologist who examined the slides was blind to group allocation. Under a
ight microscope, inflammation, edema, epithelization, neovascularization, necrosis,
broblast proliferation, and collagen synthesis were evaluated and compared sepa-
ately for each group. The following scoring system was used in the evaluations: 0 
bsent; 1  minimal; 2  mild; 3  severe.20
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Statistical analyses were performed using SPSS 15.0 for Windows (SPSS Inc.,
hicago, Illinois), and the results were analyzed using the Kruskal-Wallis test and the
ukey post-hoc (nonparametric) test.
RESULTS
Each week, the largest lesions observed were in the control group (P  0.03)
Figure). The largest mean ulcer area measured at the end of week 3 was in the
ontrol group. Lesion areas were significantly smaller in the treatment group, in
hich EPO was administered (P 0.01) (Figure). Final measurements were taken on
he 28th day of the experiment. At that time, the largest ulcer area measured was in
he control group, whereas the smallest area measured was in the treatment group
Table I).
The histopathologic evaluation revealed that the scores of epithelization and
eovascularization were significantly higher in the treatment group than in the
ontrol and control with saline groups (both, P  0.001), whereas the scores for
broblast and collagen proliferation for the treatment group were only significantly
igher than the scores for the control group (P  0.002 and P  0.04, respectively).
owever, the scores for inflammation (P  0.243) and edema (P  0.130) were not
ignificantly different between any of the groups (P  0.05). Finally, the scores for
ecrosis were significantly lower in the EPO-injected group than in the control
roups (P  0.001) (Table II).
DISCUSSION
Doxorubicin is a widely used antineoplastic agent, and local skin necrosis after the
Figure. Weekly comparison of lesion areas after administering doxorubicin, doxorubicin
plus saline, or doxorubicin plus erythropoietin (EPO) in this study of the effects of
EPO on skin necrosis from doxorubicin extravasation in rats.extravasation of doxorubicin is a common and serious problem in cancer patients.2 In
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N.S¸.Y. Bilge et al.the present study, EPO appeared to accelerate the healing of the wound caused by
doxorubicin extravasation.
Various agents have been tested for their ability to reduce the tissue damage that
results from doxorubicin extravasation. Melatonin is an effective alternative treatment
because of its potent antioxidant properties, such as oxygen free radical scavenging,
upregulation of antioxidants, and downregulation of pro-oxidant enzymes.21 Dapsone
is a leukocyte inhibitor and effectively reduces inflammation, but it plays only a small
role in the treatment of doxorubicin extravasation injuries.22 Heparin fractions have
been tested and have been reported to have beneficial effects on ulcer size and rates by
increasing new vessel formation and inhibiting coagulation.23 Dexrazoxane, a topo-
isomerase II catalytic inhibitor that antagonizes doxorubicin, has been approved by
the US Food and Drug Administration and protects against the free radical toxicity
induced by anthracyclines.11 The study by Vargel et al19 monitored the effects of
ranulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-
timulating factor (GM-CSF) on the healing of skin necrosis caused by doxorubicin
xtravasation. Both G-CSF and GM-CSF induce endothelial cell proliferation and
ifferentiation, resulting in angiogenesis.19
EPO is known to have an angiogenic effect, which is an important step in wound
ealing.20 It has proven beneficial effects on wound healing in genetically diabetic
mice9 and ischemic skin wounds.5 We used the same study design used by Vargel et
l,19 and we chose EPO because of its possible beneficial effects on wound healing
based on previously reported data.5,6,9 In the present study we used the same dose of
PO that Galeano et al9 used in the experimental study, in which EPO was reported
to stimulate wound healing in genetically diabetic mice. We chose to use a single
dose of EPO because it has been reported that a single dose accelerates wound
epithelization, reduces wound cellularity, and induces the maturation of new micro-
Table I. Comparison of the lesion areas measured each week after administering doxoru-
bicin, doxorubicin plus saline, or doxorubicin plus erythropoietin (EPO) in this
study of the effects of EPO on skin necrosis from doxorubicin extravasation in
rats.
Group
Lesion Areas (mean ranks)
Week 1 Week 2 Week 3 Week 4
1: Doxorubicin 20.09 21.00 21.45 20.82
2: Doxorubicin  saline 18.70 16.45 15.90 15.85
3: Doxorubicin  EPO 8.80* 10.05† 10.10† 10.85†
P 0.007 0.021 0.013 0.03
*P  0.05: Group 3 is significantly different from groups 1 and 2.
†P  0.05: Group 3 is significantly different from group 1.vascular formation, whereas using repetitive doses of EPO impairs the healing
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Table II. Mean values of histopathologic scores and comparisons between the doxorubicin, doxorubicin plus saline, and doxorubicin
plus erythropoietin (EPO) groups in this study of the effects of EPO on skin necrosis from doxorubicin extravasation in rats.
Group
Light Microscopic Examination Scores (mean ranks)
Inflammation Edema Epithelization Neovascularization Necrosis
Fibroblast
Proliferation
Collagen
Formation
1: Doxorubicin 18.45 15.50 10.73 9.05 21.82 10.59 13.50
2: Doxorubicin  saline 16.75 20.05 13.00 13.75 18.15 14.80 15.05
3: Doxorubicin  EPO 12.55 12.50 25.90* 25.90* 7.45* 23.15† 19.70‡
P 0.243 0.130 0.001 0.001 0.001 0.002 0.04
*P  0.001: Group 3 is significantly different from groups 1 and 2.
†P  0.005: Group 3 is significantly different from group 1.
‡P  0.05: Group 3 is significantly different from group 1.
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N.S¸.Y. Bilge et al.process, as indicated by delayed epithelization, high wound cellularity, and lack of
maturation of the microvascular networks.24
We observed that doxorubicin caused a smaller ulcer in the group in which saline
as administered than in the group in which only doxorubicin was injected. This
esult is in agreement with results of the study by Vargel et al.19 However, Vargel et
l19 also observed that CSFs, like EPO, were statistically more effective, and the
uthors hypothesized that growth factors regulate and coordinate the important steps
f wound healing by increasing angiogenesis. The sizes of the lesions in each group
id not change after the first week. The EPO-injected group had the smallest lesion
reas from the begining of the study. Once doxorubicin is extravasated, it can persist
n tissue for weeks2; therefore, the stability of the necrosis area supports the hypoth-
esis that EPO prevents the enlargement of tissue damage.
At the end of the experiment, ulcerated skin and the underlying tissues were
excised to histopathologically evaluate inflammation, edema, epithelization, neovas-
cularization, necrosis, fibroblast proliferation, and collagen formation. These param-
eters are the most important steps in skin lesion formation and wound healing. In
previously published studies, investigators have stated that doxorubicin causes direct
toxic effects in tissues without causing inflammation. In support of the literature, this
study did not find significant differences in inflammation between the tested
groups.25
Neovascularization and epithelization as important steps of wound healing were
ignificantly better in the EPO-injected group. Jaquet et al26 found that EPO
stimulates capillary proliferation 220% more than physiologic conditions. Buemi et
al5 found that recombinant human erythropoietin (rHuEPO) induced the healing of
ischemic skin necrosis by increasing neovascularization and dermal regeneration by
promoting the proangiogenic phenotype and stimulating early and late angiogenic
features. In an experimental study on diabetic rats, Galeano et al9 observed that
HuEPO improves impaired wound healing both in diabetic and nondiabetic rats.
hese data support the hypothesis that EPO may have a physiologic role in angio-
enesis, which is the most important step of wound healing.
In a separate study, Galeano et al6 reported that rHuEPO enhanced burn wound
ealing by reducing inflammatory cell infiltration and edema and that it also
timulated dermal and epidermal regeneration, fibroblast proliferation, and new
apillary formation. Sayan et al20 investigated the effects of systemic EPO adminis-
ration on wound healing. In the EPO-treated group, increased re-epithelization,
ollagen synthesis, and VEGF synthesis were reported. The histopathologic evalua-
ion of the tissue samples revealed that rHuEPO stimulates dermal organization and
ngiogenesis as a result of induced VEGF synthesis, as stated in previously published
tudies.20 We had similar results in our study, such as increased fibroblast prolifer-
ation, collagen synthesis, and epithelization in the EPO-treated group.
The limitations of this study are the short time period between doxorubicin
extravasation and EPO injection and doxorubicin injection and the administration of
EPO before the onset of skin necrosis. The small number of rats used in this study
may be another limiting factor.
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Current Therapeutic ResearchCONCLUSIONS
To our knowledge, this is the first study in which EPO has been used as an alternative
treatment for doxorubicin-induced tissue necrosis. In the 31 female Sprague-Dawley
rats tested, we observed that EPO prevents the augmentation of the necrotic area and
improves the healing of skin necrosis caused by doxorubicin injection. Through
clinical trials, EPO injection may be proven to be an alternative treatment for
preventing skin necrosis resulting from doxorubicin extravasation.
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